Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$71.25MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Meeker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 414
- Beta
- 1.97
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 12.79
Financials
Revenue
$71.25M+203485.7%Net Income
$-49.30MEBITDA
$-44.06MFree Cash Flow
$-53.34MEPS (diluted)
$-0.73Shares Outstanding (diluted)
68.59M+310.0%Operating Expenses
$110.88MCash & Debt
$330.90MRevenue by Segment (annual)
$189.76MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $189.76M | $-196.54M | $-3.11 |
| 2024 | $130.13M | $-260.60M | $-4.34 |
| 2023 | $77.43M | $-184.68M | $-3.20 |
| 2022 | $23.64M | $-181.12M | $-3.51 |
| 2021 | $3.15M | $-69.61M | $-1.37 |
| 2020 | $0.00 | $-130.73M | $-2.96 |
| 2019 | $0.00 | $-134.62M | $-3.70 |
| 2018 | $0.00 | $-74.06M | $-2.39 |
| 2017 | $0.00 | $-33.71M | $-1.26 |
| 2016 | $0.00 | $-25.87M | $-1.55 |
| 2015 | $0.00 | $-11.07M | $-1.09 |
| 2014 | $0.00 | $-6.49M | $-0.64 |
| 2013 | $0.00 | $-21.43M | $-0.43 |
| 2012 | $0.00 | $-18.13M | $-0.36 |
Valuation
RYTMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·20d ago·Positive
Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…ts across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company's work in rare melanocortin-4 receptor (MC4R) pathway diseases…
View source ↗ - News (Marketaux)finance.yahoo.com·43d ago·Positive
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can A little-known biotech, Rhythm [+319 characters]
View source ↗ - Newsglobenewswire.com·50d ago·Neutral
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer BOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17.
View source ↗ - Newsbenzinga.com·54d ago·Neutral
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $-0.72 per share
Typical surprise -4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-0.73 vs $-0.81beat
- Tue, May 5$-0.83 vs $-0.86beat
- Thu, Feb 26$-0.73 vs $-0.79beat
- Tue, Nov 4$-0.82 vs $-0.72miss
- Tue, Aug 5$-0.75 vs $-0.66miss
- Wed, May 7$-0.81 vs $-0.69miss
Estimates and results for RYTM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RYTM officers and directors.
- Bought
- —
- Sold
- $34.2m
0 trades
32 trades
- Meeker David Psold
- Meeker David Psold
- Meeker David Psold
- Meeker David Psold
- Meeker David Psold
- Smith Hunter Csold
- Smith Hunter Csold
- Smith Hunter Csold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RYTM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.